Presented by ATSE Victorian Division
Thursday 3 June
Webinar: 6.30pm-7.30pm AEST
Fellows and guests are invited to join Professor Tony Burkitt and Brendan Fafiani for an engaging talk on the commercialisation of medical devices, hosted by ATSE’s Victorian Division.
The translation of research into commercial outcomes is arduous and requires engagement well beyond the academic domain. Engineers and technologists are needed, but so is commercial expertise. The presentations will discuss the hurdles that must be overcome to bring a research proposal to market.
Open to all Fellows and their guests.
Fellows are encouraged to circulate the event information to their networks.
Due to the seven-day lockdown in Melbourne commencing at midnight on Thursday 27 May, this event will now be hosted online only.
Professor of Bio-Signals and Bio-Systems, University of Melbourne
Professor Anthony Burkitt was the Director of Bionic Vision Australia (2010-2016), a Special Research Initiative in Bionic Vision Science and Technology of the Australian Research Council (ARC). He successfully led the project though: Project conception, securing $50 million in ARC funding, the research and development programs that led to the development of a prototype bionic eye (suprachoroidal retinal implant), the successful implantation in three patients, and the establishment of the company Bionic Vision Technologies (BVT) with US$18M of venture capital for the ongoing commercial and clinical development of the technology.
In addition to his work on the bionic eye, Professor Burkitt’s research encompasses computational neuroscience, brain-computer interfaces, neuro-engineering, cochlear-implant speech processing and bio-signal processing for epilepsy.
Chief Executive Officer, Cyban
Brendan is recognised as a medical technology expert with global experience in Medical Device Product Development, Operations, Quality Management, Regulatory Affairs, Manufacturing and Supply. Brendan has successfully developed, achieved regulatory approval, launched, and enhanced a range of medical devices from software to auto-injectors and diagnostics in start-ups and large commercial organisations.
Brendan is the CEO of Cyban, which is focused on commercialising a non-invasive Brain Pulse Oximeter. He was previously a Vice-President of Product Development & GM Australia at Global Kinetics commercialising their novel offering across 18 markets. He has held positions in the global headquarters of Merck KGaA’s medical device division as a Project Manager and later Associate Director of Reliability, Support & Maintenance overseeing the lifecycle management of a large device portfolio.